



## **Rocket Pharmaceuticals to Present at the 2021 Cell & Gene Meeting on the Mesa**

October 7, 2021

CRANBURY, N.J.--(BUSINESS WIRE)--Oct. 7, 2021-- [Rocket Pharmaceuticals, Inc.](#) (NASDAQ: RCKT), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today announces that Gaurav Shah, M.D., chief executive officer, will deliver an in-person company presentation at the 2021 Cell & Gene Meeting on the Mesa, being held as a hybrid conference virtually and in Carlsbad, CA. The Rocket Pharmaceuticals presentation will take place on Tuesday, October 12 at 2:15 p.m. PST.

A live audio webcast of the presentation will be available to registered attendees within the virtual platform and within 24 hours of the Rocket presentation the video will be available for on-demand viewing.

### **About Rocket Pharmaceuticals, Inc.**

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) is advancing an integrated and sustainable pipeline of genetic therapies that correct the root cause of complex and rare childhood disorders. The Company's platform-agnostic approach enables it to design the best therapy for each indication, creating potentially transformative options for patients afflicted with rare genetic diseases. Rocket's clinical programs using lentiviral vector (LVV)-based gene therapy are for the treatment of Fanconi Anemia (FA), a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer, Leukocyte Adhesion Deficiency-I (LAD-I), a severe pediatric genetic disorder that causes recurrent and life-threatening infections which are frequently fatal, Pyruvate Kinase Deficiency (PKD), a rare, monogenic red blood cell disorder resulting in increased red cell destruction and mild to life-threatening anemia, and Infantile Malignant Osteopetrosis (IMO), a bone marrow-derived disorder. Rocket's first clinical program using adeno-associated virus (AAV)-based gene therapy is for Danon disease, a devastating, pediatric heart failure condition. For more information about Rocket, please visit [www.rocketpharma.com](http://www.rocketpharma.com).

View source version on [businesswire.com](https://www.businesswire.com/news/home/20211007005343/en/): <https://www.businesswire.com/news/home/20211007005343/en/>

### **Media**

Kevin Giordano  
Director, Corporate Communications  
[kgiordano@rocketpharma.com](mailto:kgiordano@rocketpharma.com)

### **Investors**

Mayur Kasetty, M.D.  
Director, Business Development & Operations  
[investors@rocketpharma.com](mailto:investors@rocketpharma.com)

Source: Rocket Pharmaceuticals, Inc.